Fig. 2From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaTime to and duration of response in patients with clinical benefit (partial response [n = 2] or stable disease ≥4 months [n = 6]). At the time of data cutoff, stable disease was ongoing in one patientBack to article page